Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
Department of Veterinary Pathobiology and Bond Life Science Center, University of Missouri, Columbia, MO, United States.
Front Immunol. 2023 Jun 30;14:1208848. doi: 10.3389/fimmu.2023.1208848. eCollection 2023.
, a Gram-negative pathogen, has over 2500 serovars that infect a wide range of hosts. In humans, causes typhoid or gastroenteritis and is a major public health concern. In this study, SseB (the tip protein of the pathogenicity island 2 type III secretion system) was fused with the LTA1 subunit of labile-toxin from enterotoxigenic to make the self-adjuvanting antigen L-SseB. Two unique nanoparticle formulations were developed to allow multimeric presentation of L-SseB. Mice were vaccinated with these formulations and protective efficacy determined challenging the mice with serovars. The polysaccharide (chitosan) formulation was found to elicit better protection when compared to the squalene nanoemulsion. When the polysaccharide formulation was used to vaccinate rabbits, protection from challenge was elicited. In summary, L-SseB in a particulate polysaccharide formulation appears to be an attractive candidate vaccine capable of broad protection against
伤寒杆菌，一种革兰氏阴性病原体，有超过 2500 种血清型，可感染广泛的宿主。在人类中，伤寒杆菌引起伤寒或肠胃炎，是一个主要的公共卫生关注点。在这项研究中，SseB（2 型 III 型分泌系统的尖端蛋白）与肠致病性大肠杆菌的不耐热毒素的 LTA1 亚基融合，制成自佐剂抗原 L-SseB。开发了两种独特的纳米颗粒制剂，以允许 L-SseB 的多聚体呈现。用这些制剂对小鼠进行免疫接种，并通过用 血清型对小鼠进行攻毒来确定保护效力。与角鲨烯纳米乳剂相比，发现多糖（壳聚糖）制剂能更好地引发保护作用。当用多糖制剂对兔子进行免疫接种时，能引发对 的攻毒的保护。总之，颗粒状多糖制剂中的 L-SseB 似乎是一种有吸引力的候选疫苗，能够对广泛的 提供广泛保护。
